A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (?28 Days to ?5 Years of Age) and Subsequently in Neonates (<28 Days of Age), Hospitalized With Acute Respiratory

Project: Research project

Project Details

Description

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (?28 Days to ?5 Years of Age) and Subsequently in Neonates (<28 Days of Age), Hospitalized With Acute Respiratory
StatusFinished
Effective start/end date8/26/21 → 10/26/22

Funding

  • JANSSEN RESEARCH & DEVELOPMENT, LLC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint